Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31501528 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP3A4ALDH1A1TSHRLMNA | |
| SCHEMBL5760051 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP3A4ALDH1A1TSHRLMNA | |
| SCHEMBL17309424 | 0.84 | TSHR (0.43) | CYP1A2CYP3A4ALDH1A1TSHRLMNA | |
| SCHEMBL18263710 | 0.82 | SLC6A2 (0.46) | CYP1A2CYP3A4ALDH1A1TSHRLMNA | |
| SCHEMBL28225638 | 0.81 | KDM4E (0.44) | CYP1A2CYP3A4ALDH1A1TSHRLMNA | |
| SCHEMBL16696883 | 0.78 | SLC6A2 (0.50) | CYP1A2CYP3A4ALDH1A1TSHRLMNA | |
| SCHEMBL6052780 | 0.78 | CYP1A2 (0.45) | CYP1A2CYP3A4ALDH1A1TSHRLMNA | |
| SCHEMBL4807002 | 0.77 | CYP1A2 (0.47) | CYP1A2CYP3A4ALDH1A1TSHRLMNA | |
| SCHEMBL14928678 | 0.76 | TSHR (0.48) | CYP1A2CYP3A4ALDH1A1TSHRLMNA | |
| SCHEMBL30211265 | 0.76 | TSHR (0.48) | CYP1A2CYP3A4ALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421200-B2 | Manganese-catalysed hydrogenation of esters | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2025-09-23 | — | — | US | disclosed |
| US-12281058-B2 | Manganese catalysts and their use in hydrogenation of ketones | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2025-04-22 | — | — | US | disclosed |
| WO-2024100405-A1 | CATALYTIC HYDROGENATION PROCESS | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2024-05-16 | — | — | WO | disclosed |
| EP-3737663-B1 | MANGANESE-CATALYSED HYDROGENATION OF ESTERS | UNIV COURT UNIV ST ANDREWS (GB) | 2023-02-22 | — | — | EP | disclosed |
| US-20220119329-A1 | Manganese Catalysts and Their Use in Hydrogenation of Ketones | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2022-04-21 | — | — | US | disclosed |
| EP-3908588-A1 | MANGANESE CATALYSTS AND THEIR USE IN HYDROGENATION OF KETONES | University Court of The University of St Andrews (GB) | 2021-11-17 | — | — | EP | disclosed |
| US-20210053932-A1 | MANGANESE-CATALYSED HYDROGENATION OF ESTERS | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2021-02-25 | — | — | US | disclosed |
| EP-3737663-A1 | MANGANESE-CATALYSED HYDROGENATION OF ESTERS | University Court of The University of St Andrews (GB) | 2020-11-18 | — | — | EP | disclosed |
| WO-2020144476-A1 | MANGANESE CATALYSTS AND THEIR USE IN HYDROGENATION OF KETONES | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2020-07-16 | — | — | WO | disclosed |
| EP-1748975-B1 | METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE 3-ALKYL CARBOXYLIC ACIDS AND THE INTERMEDIATE PRODUCTS THEREOF | WACKER CHEMIE AG (DE) | 2008-02-13 | — | — | EP | disclosed |
| EP-1325003-B1 | 7-CHLORO-4-HYDROXY-2-(2-PYRIDYLETHYL)-1,2,5,10-TETRAHYDROPYRIDAZINO 4,5-B|QUINOLINE-1,10-DIONE AND THE USE THEREOF FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| US-6933297-B2 | 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione and the use thereof for the treatment of pain | ASTRAZENECA AB (CH) | 2005-08-23 | — | — | US | disclosed |
| US-20040053930-A1 | 7-Chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione and the use thereof for the treatment of pain | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053930-A1 | 7-Chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione and the use thereof for the treatment of pain | HTR5A, OPRK1, OPRD1 | CYP1A2 66/4885CYP3A4 40/4885ALDH1A1 179/4885 |
| US-12281058-B2 | Manganese catalysts and their use in hydrogenation of ketones | CYC1, SCO2, MT-CO3 | CYP1A2 1170/4885CYP3A4 1922/4885ALDH1A1 2055/4885 |
| US-12421200-B2 | Manganese-catalysed hydrogenation of esters | ADH5, HDHD5, ADH1A | CYP1A2 337/4885CYP3A4 93/4885ALDH1A1 1003/4885 |
| US-20210053932-A1 | MANGANESE-CATALYSED HYDROGENATION OF ESTERS | ADH5, HDHD5, ADH1A | CYP1A2 337/4885CYP3A4 93/4885ALDH1A1 1003/4885 |
| US-20220119329-A1 | Manganese Catalysts and Their Use in Hydrogenation of Ketones | CYC1, SCO2, MT-CO3 | CYP1A2 1170/4885CYP3A4 1922/4885ALDH1A1 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.